Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2016 by Vanquish Oncology, Inc.
University of Illinois at Chicago
Information provided by (Responsible Party):
Oana Danciu, MD, University of Illinois at Chicago Identifier:
First received: January 30, 2015
Last updated: May 1, 2016
Last verified: May 2016
This Phase I dose escalation study will evaluate Procaspase Activating Compound-1 (PAC-1), a small molecule that activates procaspase -3 to caspase-3, resulting in apoptosis of cancer cells, in patients with advanced malignancies. PAC-1 is taken orally on days 1-21 of a 28-day cycle. The maximum tolerated dose (MTD) of PAC-1 (5 dose levels) will be determined using a modified-Fibonacci dose-escalation 3+3 design. Treatment continues until disease progression, unacceptable toxicity, physician discretion, or patient refusal.

Condition Intervention Phase
Breast Cancer
Gastrointestinal Cancers
Genitourinary Cancers
Gynecologic Cancers
Head and Neck Cancers
Thoracic Cancers
Solid Tumors
Drug: PAC-1
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: (STM-03) Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies

Resource links provided by NLM:

Further study details as provided by Vanquish Oncology, Inc.:

Primary Outcome Measures:
  • Maximum Tolerated Dose [ Time Frame: Up to 30 days post last dose ]
    The primary objective of this study component is to determine the maximum tolerated dose (MTD) of PAC-1 in patients with advanced, previously treated malignancy, by evaluation of toxicity and tolerability.

Secondary Outcome Measures:
  • Adverse Effects [ Time Frame: Up to 30 days post final dose ]
    Characterize adverse effects (AE) of PAC-1 in patients with advanced malignancy.

  • Disease Response based on RECIST Criteria for patients with solid tumors [ Time Frame: Up to 8 weeks following final dose ]
    Evaluate clinical response of PAC-1 in patients with solid tumors (RECIST v 1.1).

  • Disease Response based on Deauville PET Criteria for patients with lymphoma [ Time Frame: Up to 8 weeks following final dose ]
    Evaluate clinical response of PAC-1 in patients with lymphoma (Deauville PET Criteria).

Estimated Enrollment: 65
Study Start Date: February 2015
Estimated Primary Completion Date: March 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Open label
Using a dose-escalation design, PAC-1 is administered orally on days 1-21, at the assigned dose, of a 28-day cycle.
Drug: PAC-1
PAC-1 is taken orally on days 1-21 of a 28-day cycle.
Other Name: Procaspase Activating Compound-1


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female ≥ 18 years of age
  2. Diagnosis of advanced solid tumor or hematologic malignancy (limited to lymphoma) that has failed or become intolerant to standard therapy
  3. Has measurable disease, defined as at least 1 tumor that fulfills the criteria for a target lesion according to RECIST 1.1, or lymphoma that fulfills the Deauville PET Criteria
  4. Has an ECOG PS of 0, 1, or 2
  5. Has total bilirubin < 1.5 mg/dL, serum albumin > 3.0 gm/dL, AST and ALT < 1.5 ULN or < 3 x ULN for subjects with known hepatic metastases
  6. Has serum creatinine < 1.5 × ULN
  7. Has hemoglobin ≥ 10 g/dL, ANC ≥ 1.5 × 109/L, and platelet count ≥ 100 × 109/L
  8. Must be able to take oral medication and to maintain a fast as required for 2 hours before and 1 hour after capsule(s) administration
  9. Must be willing and able to comply with study
  10. Has read, understood, and signed the ICF
  11. Women of childbearing potential must not be pregnant or breast-feeding. In addition, a medically acceptable method of birth control must be used or total abstinence. Women who are postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) are not considered to be WOCP
  12. Men who are not surgically or medically sterile must agree to use an acceptable method of contraception. Male patients with female sexual partners who are pregnant, possibly pregnant, or who could become pregnant during the study must agree to use condoms at least one month after the last dose of study drug. Total abstinence for the same study period is an acceptable alternative
  13. Prior systemic treatments for metastatic disease are permitted but may not be ongoing, including targeted therapies, biologic response modifiers, chemotherapy, hormonal therapy, or investigational therapy
  14. Willingness to donate blood for biomarker studies related to the type of therapies used in this trial and the tumor types being treated

Exclusion Criteria:

  1. Had surgery within 4 weeks prior to study treatment except for minor procedures (hepatic biliary stent placement is allowed)
  2. Gliomas are excluded, as well as any history of brain metastases, seizures or underlying brain injury
  3. May not have received cytotoxic chemotherapy, targeted therapies, biologic response modifiers, chemotherapy, and hormonal therapy within the last 3 weeks, or nitrosureas within the last 6 weeks prior to study treatment.
  4. Has a history of blood clots, pulmonary embolism, or DVT unless controlled by anticoagulant treatment
  5. Has a history of an arterial thromboembolic event within the prior six months including CVA, TIA, MI, or unstable angina
  6. Has uncontrolled HIV or hepatitis B or C
  7. Has any clinically significant infection
  8. Has any other severe, uncontrolled medical condition, including uncontrolled DM or unstable CHF
  9. Radiation therapy to more than 25% of the bone marrow
  10. Prior allogeneic bone marrow or organ transplantation
  11. > Grade 1 peripheral neuropathy within 14 days before enrollment.
  12. Patient has received other investigational drugs with 14 days before enrollment
  13. Other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that may increase the risk associated with study participation
  14. Abnormalities on 12-lead electrocardiogram (ECG) considered by the investigator to be clinically significant (such as acute ischemia, left bundle branch block, ventricular arrhythmias) or baseline prolongation of the rate-corrected QT interval (e.g., repeated demonstration of QTc interval > 480 milliseconds)
  15. Presence of any non-healing wound, fracture, or ulcer
  16. Has any condition that, in the opinion of the investigator, might jeopardize the safety of the patient or interfere with protocol compliance
  17. Has any mental or medical condition that prevents the patient from giving informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02355535

Contact: Oana C. Danciu, M.D. 312-996-1581
Contact: Meredith Russell, R.N. 312-355-5112

United States, Illinois
University of Illinois at Chicago Recruiting
Chicago, Illinois, United States, 60612
Contact: Oana Danciu, MD    312-996-1581   
Contact: Alisha Williams, RN    (312) 413-2746   
United States, Maryland
Johns Hopkins Kimmel Cancer Center Recruiting
Baltimore, Maryland, United States, 21231
Contact: Matthias Holdhoff, MD, PhD    410-955-8804   
Sponsors and Collaborators
Vanquish Oncology, Inc.
University of Illinois at Chicago
Principal Investigator: Oana C Danciu, M.D. University of Illinois at Chicago
  More Information

Responsible Party: Oana Danciu, MD, Assistant Professor, University of Illinois at Chicago Identifier: NCT02355535     History of Changes
Other Study ID Numbers: 2015-0057
Study First Received: January 30, 2015
Last Updated: May 1, 2016

Keywords provided by Vanquish Oncology, Inc.:
solid tumors

Additional relevant MeSH terms:
Head and Neck Neoplasms
Gastrointestinal Neoplasms
Urogenital Neoplasms
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplasms by Site
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases processed this record on April 28, 2017